NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?

Nature Reviews Clinical Oncology, Published online: 25 April 2024; doi:10.1038/s41571-024-00896-wThe FDA has approved nanoliposomal irinotecan, 5-fluorouracil, leucovorin and oxaliplatin (NALIRIFOX) for patients with metastatic pancreatic adenocarcinoma on the basis of results from the NAPOLI 3 trial, in which this four-drug regimen improved overall survival relative to a doublet regimen. Here we discuss how, in the context of prior results from the PRODIGE 4 trial testing 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (modified FOLFIRINOX), NALIRIFOX does not seem to raise the bar, but rather exposes patients and health-care systems to financial toxicities.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research